BioVie Inc (BIVI): Rasio rega marang bathi tumrap wutah

Simbol lan logo merek BioVie Inc. (BIVI)

Phase III trials of Alzheimer's drugs have become the growth driver for BioVie Inc. (BIVI), which is currently determining the price action. The current PEG growth stock filter on GURU.Markets contains the 0.00 mark, reflecting the latest data. Patent success will ensure high profit scalability, while the overall business value relies on cirrhosis treatment results and the neuroprotective effect of new drugs.

BioVie (BIVI): Pangali rega marang bathi tumrap wutah saka 04.07.2022 nganti 11.11.2026

Rincian metrik lan analitis perusahaan BioVie Inc. (BIVI)

- rega saham lan konsensus proyeksi valuasi:
Bagan owah-owahan rega biovieinc.com|BIVI - Bagan rega target
- data kapitalisasi bursa:
Nilai pasar BioVie Pharma|BIVI - Nilai Perusahaan
- statistik nilai buku emiten:
Aset Bersih saben Saham BioVie|BIVI - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku biovieinc.com|BIVI - Total Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Modal BioVie Inc.|BIVI - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal biovieinc.com|BIVI - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku BioVie Pharma|BIVI - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak BioVie|Likuiditas darurat biovieinc.com
- data bathi resik lan rasio valuasi:
BIVI - Penghasilan resik|Bathi sing dikarepake BioVie Inc.|BIVI - Pangali P/E|Kapitalisasi marang proyeksi bathi biovieinc.com|BIVI - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BioVie Pharma|BIVI - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku BioVie|BIVI - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan biovieinc.com|BIVI - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep BioVie Inc.
Analisis umum perusahaan:BioVie Inc BIVI
Produk seri BioVie

The PEG ratio compares the market value of earnings to their growth rate to determine whether an asset's valuation is fair. By analyzing the P/E ratio relative to growth dynamics, an investor can assess the balance between price and the speed of business development. For BioVie Inc. (BIVI), this metric is critical because capitalization depends on the outcomes of NE3107 trials. High cash burn makes earnings growth hypothetical. Consequently, the indicator reveals the risk of overpaying for uncertain future successes.

Perusahaan pesaing

ARWR (Arrowhead Pharma) - Koefisien bali modal nimbang wutah|Rasio rega marang bathi tumrap wutah Mirum Pharma MIRM|Dynavax - Rasio rega marang bathi tumrap wutah|Arbutus Biopharma - Pangali PEG|Kapitalisasi marang bathi resik kanthi nimbang wutah inventivapharma.com IVA|GYRE (Gyre Therapeutics) - Pangali rega marang bathi tumrap wutah|ASMB (Assembly Bio) - Rasio rega marang bathi tumrap wutah|GALT (Galectin Therapeutics, Inc.) - Pangali PEG|Rega marang bathi kanthi panyesuaian wutah Genfit Corp GNFT|Rasio rega marang bathi tumrap wutah DURECT Corporation (DRRX)|ALGS (aligos.com) - Koefisien bali modal nimbang wutah|Pangali PEG GLMD (Galmed Pharmaceuticals Ltd.)|ENDRA Life Sciences Inc - Rasio rega marang bathi tumrap wutah|Hepion Pharma - Pangali PEG